CLOS
NKTR icon

Compagnie Lombard Odier SCmA’s Nektar Therapeutics NKTR Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-60
Closed -$44K – 598
2018
Q2 		$44K Sell
60
-297
-83% -$342K ﹤0.01% 450
2018
Q1 		$568K Buy
+357
New +$460K 0.02% 210

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Compagnie Lombard Odier SCmA's NKTR Position: Q3 2018 in Review

Compagnie Lombard Odier SCmA sold out of Nektar Therapeutics (NKTR) in Q3 2018, closing a stake of 60 shares — an estimated $44K sold.

Compagnie Lombard Odier SCmA first reported a position in NKTR in Q1 2018 and held it in 2 quarters. The position peaked at $568K in Q1 2018. 389 funds tracked by Wall St. Rank hold NKTR as of Q3 2018.

  • Compagnie Lombard Odier SCmA reported no remaining Nektar Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 60 Nektar Therapeutics shares in Q3 2018, an estimated $44K.
  • Compagnie Lombard Odier SCmA first reported a position in Nektar Therapeutics in Q1 2018 and held it in 2 quarters.
  • Compagnie Lombard Odier SCmA's Nektar Therapeutics position peaked at $568K in Q1 2018.
  • 389 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2018.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2018, filed 13 Nov 2018.